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 The emergence of human immunodeficiency virus 
(HIV) and its synergistic association with tuberculosis 
(TB) pose a great challenge to the health systems in 
developing countries. TB is the most life threatening 
opportunistic infection among HIV patients accounting 
40 per cent of acquired immunodeficiency syndrome 
(AIDS) deaths in Asia1. Interaction between chemokine 
and chemokine receptors and their expression patterns 
regulate migration of cells involved in immune response 
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Background & objectives: Variability in the clinical outcome of persons exposed to and infected with 
HIV-1 and tuberculosis (TB) is determined by multiple factors including host genetic variations. The 
aim of the present study was to find out whether chemokine, chemokine receptor and DC-SIGN gene 
polymorphisms were associated with susceptibility or resistance to HIV and HIV-TB in south India.
Methods: CCR2 V64I (G/A), monocyte chemoattractant protein-1 (MCP-1) -2518 A/G, stromal cell 
derived factor-1α (SDF-1α) 3’UTR G/A and DC-SIGN gene polymorphisms were studied by polymerase 
chain reaction based methods in HIV-1 infected patients without TB (n=151), with pulmonary TB (PTB) 
(n=81) and extrapulmonary TB (n=31), 155 PTB patients without HIV and 206 healthy controls. 
Results: The genotype frequencies of CCR2 V64I, MCP-1 -2518 and DC-SIGN polymorphisms did not 
differ significantly between the study groups. A significantly increased frequency of GG genotype of 
SDF-1α polymorphism was observed among HIV+PTB+ patients compared to healthy controls (P=0.009, 
Pc=0.027).
Interpretation & conclusions: Our data suggest that GG genotype of SDF-1α 3’UTR polymorphism may 
be associated with susceptibility to PTB in HIV-1 infected patients. A better understanding of genetic 
factors that are associated with TB could help target preventive strategies to those HIV patients likely 
to develop tuberculosis.  
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to tuberculosis (TB) as well as HIV and contribute 
to the pathogenesis of the disease2-4. Dendritic cell-
specific intercellular adhesion molecule -3- grabbing 
non integrin (DC-SIGN), a C type lectin expressed 
on dendritic cells recognize pathogens through their 
carbohydrate structure and internalize the pathogen 
for antigen presentation. HIV and Mycobacterium 
tuberculosis target DC-SIGN by different mechanisms 
to promote their survival5. 
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 Variability in the clinical outcomes of persons 
exposed to and infected with HIV-1 and tuberculosis 
is determined by multiple factors including host 
genetic variations. Variants of CC chemokine receptor 
- CCR2, Monocyte chemoattractant protein-1 (MCP-1) 
and stromal cell derived factor-1α (SDF-1α) and DC-
SIGN genes have been shown to be associated with 
susceptibility or resistance to HIV-1 manifestations and 
disease progression3,6-8.  Polymorphisms in MCP-1 and 
DC-SIGN genes have also been shown to be associated 
with susceptibility to tuberculosis9,10. Although a few 
studies on chemokine, chemokine receptor and DC-
SIGN exon 4 repeat number polymorphisms have been 
reported in north Indian (Aryan descent) HIV patients 
and healthy controls11-14, there is a dearth of reports 
on HIV patients with and without TB of south Indian 
(Dravidian descent) origin. So far only one study has 
been carried out in healthy individuals of tribes and 
Muslim ethnic groups of Andhra Pradesh, south India15. 
The present study was therefore carried out to find out 
whether CCR2, MCP-1, SDF-1α and DC-SIGN gene 
polymorphisms are associated with susceptibility or 
resistance to HIV and HIV associated TB in south 
India. 
Material & Methods
Study subjects: The study population comprised 151 
HIV-1 seropositive subjects without TB (HIV+TB-) 
(64 male, mean age ± SD : 32.1 ± 6.9 yr; 87 female, 
28.6 ± 6.7 yr), 81 HIV-1 seropositive subjects with 
pulmonary TB (HIV+PTB+) (60 male,  35.3 ± 6.7 yr; 21 
female,  31.9 ± 6.5 yr), 31 HIV-1 seropositive subjects 
with extrapulmonary TB (HIV+ETB+) (23 male,  33.5 
± 4.5 yr; 8 female,  31.6 ± 9.0 yr), 155 HIV negative 
pulmonary TB positive (HIV-PTB+) (102 male,  37.8 
± 10.8 yr; 53 female,  30.2 ± 9.0 yr) recruited from the 
HIV and TB clinics of Tuberculosis Research Centre 
(TRC) and its subcentres viz., Government General 
Hospital, Chennai, and Government Hospital of 
Thoracic Medicine, Tambaram Sanatorium, Chennai, 
and 206  healthy controls (118 male, mean age ± SD : 
31.3 ± 8.4 yr; 88 female,  30.9 ± 8.7 yr). The diagnosis 
of tuberculosis was confirmed by clinical, radiographic 
and/or bacteriological observations (pulmonary TB) 
or by the presence of acid fast bacilli in the aspirated 
fluid/tissue (extrapulmonary TB). The diagnosis of 
HIV-1 was made using two rapid tests (HIV-1 tridot, J. 
Mitra, India; CombAids, Span diagnostics, India), and 
a positive result was confirmed by a third test (Western 
Blot, J. Mitra, India), according to the manufacturer’s 
instruction. 
 Among the 81 HIV+PTB+ patients, 74 had smear 
positive PTB while 7 had smear negative PTB. Among 
the HIV patients with ETB, 11 had lymph node TB, 5 had 
miliary TB and 5 had pleural effusion. Seven patients 
had both pulmonary TB and one of the extrapulmonary 
forms of TB such as lymph node TB, pleural effusion, 
pneumothorax, tuberculoma and abdominal TB. Two 
patients had pericardial effusion while one patient had 
both lymph node TB and pleural effusion. The clinical 
characteristics of HIV patients with tuberculosis of the 
present study have been described earlier16. 
 The healthy controls group included university 
students, laboratory personnel and volunteers of 
Tuberculosis Research Centre who were physically 
normal and asymptomatic for TB and willing to 
participate in the study. Healthy controls were not 
diagnosed for HIV since the prevalence of HIV is 
0.34 per cent (less than 1%) among adults of general 
population according to the latest revised estimates 
released by National AIDS Control Organization 
(NACO)17. Patients and controls were recruited 
consecutively from January 2004 to December 2006. 
The present study was approved by the institutional 
ethical committee, and a written informed consent was 
obtained from all the participants of the study. Both the 
patients and controls were of Tamil speaking Dravidian 
descent of Tamil Nadu living in and around Chennai. 
Genotyping of CCR2, MCP-1, SDF-1α and DC-SIGN 
exon4 repeat polymorphisms: Genomic DNA was 
isolated from peripheral blood mononuclear cells and 
granulocytes obtained from the blood of patients and 
healthy controls using salting out procedure18. CCR2 
V64I (G/A), MCP-1 -2518 A/G, SDF-1α 3’UTR 
G/A genotypes were identified using polymerase 
chain reaction based restriction fragment length 
polymorphisms (PCR-RFLP) as described elsewhere19-21. 
The PCR reaction conditions for CCR2 V64I (G/A) 
were an initial denaturation step at 94°C for 5 min 
followed by 35 cycles of denaturation at 94°C for 
30 sec, annealing at 62°C for 30 sec, extension at 
72°C for 1 min and a final extension at 72°C for 2 
min. For MCP-1 -2518 A/G and SDF-1α 3’UTR G/A 
polymorphisms, the annealing temperature for PCR was 
60 and 58°C respectively and all other conditions were 
the same as that for CCR2 V64I (G/A). Number of 69 
base pair repeats in the DC-SIGN exon4 was identified 
using PCR as described earlier22. The PCR reaction 
conditions for DC-SIGN polymorphism were same as 
that of CCR2 V64I (G/A) PCR, except that annealing 
was done at 65°C. PCR was set in a programmable 
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thermal cycler (PTC-225, MJ Research Inc, MA, USA). 
The sequences of primers (Sigma Genosys, Bangalore, 
India) and restriction digestion enzymes (New England 
BioLabs, USA) used for genotyping as well as the size 
of PCR and restriction digestion products are given in 
Table I.
Statistical analysis: Allele and genotype frequencies of 
individual polymorphisms were determined by direct 
counting. Confirmation to Hardy-Weinberg equilibrium 
was tested using χ2 test with one degree of freedom. 
Frequencies of genotypes, of patients and healthy 
controls were compared by χ2 test or Fisher’s exact test 
wherever applicable, P values with Yates correction 
and odds ratio (OR) with 95 percent confidence 
intervals were calculated using Statcalc program (Epi 
info version 6.0.4, CDC, Atlanta, GA, July 1996). 
HIV+TB+ patients with different clinical features 
were grouped as HIV+PTB+ and HIV+ETB+ since the 
number of patients in each extrapulmonary form of TB 
(ETB) group was very low16. P<0.05 was considered 
significant. Power calculations were performed using 
the software GraphPad StatMate version 2.
Results
 Allele and genotype frequencies of CCR2 V64I 
(G/A), MCP-1 -2518 A/G, SDF-1α 3’UTR G/A and 
DC-SIGN exon 4 repeat polymorphisms among 
different study groups are presented in Tables II and 
III. Genotype frequencies of all the polymorphisms 
were in Hardy-Weinberg equilibrium among healthy 
controls.
 The allele and genotype frequencies of CCR2 
V64I (G/A), MCP-1 -2518 A/G, SDF-1α 3’UTR G/A 
and DC-SIGN exon 4 repeat polymorphisms were not 
different between total HIV patients (includes both 
HIV patients with and without TB) and healthy controls 
(data not shown). When the HIV patients were stratified 
as HIV patients without TB (HIV+TB-) and with TB 
(HIV+TB+), HIV patients with PTB (HIV+PTB+) and 
HIV patients with ETB (HIV+ETB+), the allele and 
genotype frequencies of CCR2 V64I (G/A) and MCP-
1 -2518 A/G polymorphisms did not differ significantly 
between the HIV patients groups with and without 
TB as well as HIV negative TB patients compared to 
healthy controls. 
 A trend towards an increased frequency of GG 
genotype of SDF-1α 3’UTR G/A polymorphism was 
seen among HIV-PTB+ patients compared to healthy 
controls (P=0.053, OR 1.57). Significantly increased 
frequency of G allele and decreased frequency of 
A allele of SDF-1α 3’UTR G/A polymorphism was 
observed in HIV+TB+ (P=0.02) and HIV+PTB+ 
(P=0.004) patients as compared to healthy controls. 
An increased frequency of GG genotype was noticed in 
HIV+TB+ patients (P=0.037) and HIV+PTB+ patients 
in comparison to healthy controls (P=0.009; Pc=0.027) 
and no such difference was observed in HIV+ETB+ 
patients. The AA genotype of  SDF-1α 3’UTR G/A 
polymorphism was not observed in HIV+PTB+ 
patients as compared to healthy controls (P=0.037) 
and HIV+TB- patients (P=0.028).  A significantly 
decreased frequency of GA genotype was observed 
among HIV-PTB+ patients as compared to healthy 
controls (P=0.006; Pc=0.018) and a decreased trend 
was observed in HIV+PTB+ patients (P=0.08). 
 The most frequent DC-SIGN gene exon 4 repeat 
number observed was 7.5 repeat with frequencies 
more than 0.97 in all study groups. The other alleles 
Table I. Primers sequences, restriction enzymes used and restriction digestion  patterns for genotyping of CCR2 V64I (G/A), MCP-1 -2518 
A/G, SDF-1α 3’UTR G/A and DC-SIGN exon 4 repeat polymorphisms
SNPs studied Sequence of the primers Product  
size
Restriction
enzyme used
Restriction digestion  patterns
for different alleles
CCR2 V64I (G/A)
MCP-1 -2518 A/G 
SDF-1α 3’UTR G/A
DC-SIGN exon 4
repeat (rpt)
5′- GGATTGAACAAGGACGCATTTCCCC -3′
5′- TTGCACATTGCATTCCCAAAGACCC -3′ 
5′- CCGAGATGTTCCCAGCACAG -3′
5′- CTGCTTTGCTTGTGCCTCTT- 3′
5′- CAGTCAACCTGGGCAAAGCC-3′
5′- CCTGAGAGTCCTTTTGCGGG-3′
5′- CACCACACAACGACCATCTC -3′ 
5′- AGGTCCCCAGCTCCATAAGT - 3′
380 bp
930 bp
293 bp
*686/616/ 
547/478/ 
409 bps
Fok I
Pvu II
Msp I
None
G – 380 bp
A – 215 + 165 bp bands
A – 930 bp
G – 708 + 222 bp bands
G – 193 + 100 bp
A – 293 bp
None
SNPs, single nucleotide polymorphisms
* For DC-SIGN, the alleles are assigned on the basis of PCR product size; 7.5 repeat – 616 bp, 686 bp – 8.5 rpt, 547 bp – 6.5 rpt, 478 bp - 5.5 
rpt; 409 bp - 4.5 rpt 
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Table II. Allele frequencies of CCR2 V64I (G/A), MCP-1 -2518 A/G, SDF-1α 3’UTR G/A and DC-SIGN exon 4 repeat polymorphisms 
among different study groups
Alleles Controls
(n=206)
HIV+TB-
(n=151)
HIV+TB+
(n=112)
HIV+PTB+
(n=81)
HIV+ETB+
(n=31)
HIV-PTB+
(n=155)
CCR2 V64I (G/A)
G
A
MCP-1 -2518 A/G
A
G
SDF-1α 3’UTR G/A
G
A
DC-SIGN exon 4 repeats
8.5
7.5
6.5
0.913
0.087
0.658
0.342
0.749*, † 
0.251
0.003
0.997
0
0.924
0.076
0.626
0.374
0.768
0.232
0.004
0.990
0.006
0.901
0.099
0.687
0.313
0.830*
0.170
0.005
0.990
0.005
0.894
0.106
0.685
0.315
0.864†
0.136
0.006
0.994
0
0.919
0.081
0.694
0.306
0.742
0.258
0
0.970
0.030
0.880
0.120
0.686
0.314
0.784
0.216
0.003
0.994
0.003
n, Number of subjects studied
For CCR2, n = 111 in HIV+TB+, 80 in HIV+PTB+ and 154 in HIV-PTB+  
For MCP-1, n = 203 in controls, and 153 in HIV-PTB+  
For SDF-1 α, n = 205 in controls
For DC SIGN, n = 201 in controls, 150 in HIV+TB-, 108 in HIV+TB+, 78 in HIV+PTB+,  30 in HIV+ETB+   and 153 in HIV-PTB+  
With regard to DC-SIGN, the numbers 8.5, 7.5 and 6.5 represent the number of 69 base pair repeats
*Controls versus HIV+TB+ P= 0.024, Odds ratio (OR) 1.64; 95 per cent Confidence intervals (CI) 1.07-2.56
† Controls versus HIV+PTB+ P = 0.004, OR 2.14; 95 per cent CI 1.27-3.17
Table III. Genotype frequencies of CCR2 V64I (G/A), MCP-1 -2518 A/G, SDF-1α 3’UTR G/A and DC-SIGN exon 4 repeat polymorphisms 
among different study groups
Genotypes Controls
(n=206)
% GF
HIV+TB-
(n=151)
% GF
HIV+TB+
(n= 112)
%GF
HIV+PTB+
(n=81)
% GF
HIV+ETB+
(n=31)
% GF
HIV-PTB+
(n=155)
% GF
CCR2 V64I (G/A)
GG
GA
AA
MCP-1 -2518 A/G
AA
AG
GG
SDF-1α 3’UTR G/A
GG
GA
AA
DC-SIGN exon 4 repeat
8.5/7.5
7.5/7.5
7.5/6.5
84.0 (173)
14.6 (30)
1.4 (3)
45.8 (93)
39.9 (81)
14.3 (29)
55.1(113)* #, †
39.5 (81)@
5.4 (11) δ
0.5 (1)
99.5 (200)
0
84.8 (128)
15.2 (23)
0
41.1 (62)
43.0 (65)
15.9 (24)
59.6 (90)
34.4 (52)
6.0 (9) Ω
0.7 (1)
98.0 (147)
1.3 (2)
81.1 (90)
18.0 (20)
0.9 (1)
48.2 (54)
41.1 (46)
10.7 (12)
67.8 (76)†
30.4 (34)
1.8 (2)
0.9 (1)
98.2 (106)
0.9 (1)
80.0 (64)
18.8 (15)
1.2 (1)
45.7 (37)
45.7 (37)
8.6 (7)
72.8 (59)*
27.2 (22)
0 δ, Ω
1.3 (1)
98.7 (77)
0
83.9 (26)
16.1 (5)
0
54.84 (17)
29.03 (9)
16.13 (5)
54.8 (17)
38.7 (12)
6.5 (2)
0
96.7 (29)
3.3 (1)
78.6 (121)
18.8 (29)
2.6 (4)
51.0 (78)
35.3 (54)
13.7 (21)
65.8 (102)#
25.2 (39)@
9.0 (14)
0.65 (1)
98.7 (151)
0.65 (1)
n, Number of subjects studied, numbers in the parentheses represent individuals positive for that genotype, %GF = per cent genotype 
frequency
For CCR2, n = 111 in HIV+TB+, 80 in HIV+PTB+ and 154 in HIV-PTB+; For MCP-1, n = 203 in controls, and  153 in HIV-PTB+; For SDF-
1, 205 in controls; For DC SIGN, n = 201 in controls, 150 in HIV+TB-, 108 in HIV+TB+, 78 in HIV+PTB+, 30 in HIV+ETB+   and  153 in 
HIV-PTB+; With regard to DC-SIGN, the numbers 8.5/7.5, 7.5/7.5 and 7.5/6.5 represents the number of 69 base pair repeat genotypes
* Controls versus HIV+PTB+ P = 0.009, Pc = 0.027 Odds ratio (OR) 2.18; 95% Confidence intervals (CI) 1.21 - 4.03
 # Controls versus HIV-PTB+ P = 0.053, OR 1.57 95% CI 1.00 – 2.47
@Controls versus HIV-PTB+ P = 0.006 OR 0.51 95% CI 0.32 - 0.83
†Controls versus HIV+TB+ P = 0.037 OR 1.72 95% CI 1.03 -2.88
δ Controls versus HIV+PTB+ P = 0.037 OR 0 95% CI 0.00 -0.98
Ω HIV+TB- versus HIV+PTB+ P = 0.028 OR 0 95% CI 0.00 -0.92
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observed at very low frequencies included 8.5 and 6.5 
number repeats. The allele and genotype frequencies 
did not differ significantly between the study groups. 
Discussion
 The allele frequencies of CCR2 V64I, SDF-1α 
3’UTR and DC- SIGN exon 4 repeat polymorphisms in 
the present study were similar to that reported earlier in 
south and north Indian populations11-15. A significantly 
increased frequency of GG genotype of SDF-1α 
3’UTR G/A polymorphism was observed among 
HIV patients with PTB suggesting that GG genotype 
may be associated with susceptibility to PTB in HIV 
infected individuals. SDF-1α 3’UTR AA genotype was 
not observed among HIV+PTB+ patients suggesting 
its possible association with resistance to PTB in HIV 
infected individuals. SDF-1α 3’UTR GA genotype was 
observed in low frequency among HIV-PTB+ patients 
which suggests that GA genotype may be associated 
with resistance to PTB in HIV negative individuals. 
Due to the low number (n = 31) and heterogeneity in 
the forms of TB of HIV+ETB+ patients, no association 
was observed with extrapulmonary forms of TB in HIV 
patients. Since this is a cross sectional study with limited 
sample size, further follow up study in HIV patients is 
warranted. However, based on the frequencies of the 
allele associated with susceptibility (G allele of SDF-
1α 3’UTR G/A polymorphism) to PTB in HIV patients, 
the present study had power of 80 per cent to detect an 
odds ratio above 1.2.  
 The association of GG genotype with susceptibility 
to PTB in HIV patients in our study may be due to linkage 
of G/A alleles with alleles of other polymorphisms 
found elsewhere in the SDF-1α gene as described 
earlier23. Since SDF-1α is a potent lymphocyte 
chemoattractant and is involved in haematopoiesis24, 
the G allele along with the other linked alleles might 
alter SDF-1α levels and may influence recruitment 
of T lymphocyte and other immune cells to the site 
of infection as well as replenishment of lymphocytes 
and hence may be associated with susceptibility to 
PTB in HIV patients. Decreased serum SDF-1α levels 
in individuals with 3’A/3’A genotype compared to 
3’G/3’G have been reported in Spanish HIV-1 infected 
patients25. However, it has been proposed that 3’A/3’A 
genotype might be associated with overproduction of 
SDF-1 α7. No association between SDF-1α 3’UTR 
genotypes and HIV-1 infection was observed in the 
present study. This may be due to the observation 
that R5 strains that use CCR5 as co-receptor rather 
than CXCR4, receptor for SDF-1α, are preferentially 
transmitted due to the co-receptor expression patterns 
in mucosal sites associated with sexual transmission26. 
Lack of association between HIV-1 infection and SDF-
1α 3’UTR genotypes has also been reported in north 
Indian population 11. 
 Our results suggested that CCR2 V64I (G/A) 
polymorphism was not associated with susceptibility 
or resistance to HIV and TB, and similar finding 
has also been shown in north Indian population12. In 
contrary, CCR2 64I homozygosity has been reported 
to be associated with reduced risk of acquiring HIV-
1 infection from a study on HIV-1 discordant couples 
in Thailand27. Association of GG genotype of MCP-
1 -2518 A/G polymorphism with susceptibility to 
PTB has been shown in Korean and Mexican PTB 
patients 9 and another study on mixed American HIV 
patients revealed that GG genotype is associated with 
accelerated progression towards AIDS and increased 
risk of HIV associated dementia3. In the present study, 
no association between MCP-1 -2518 polymorphism 
and HIV/TB was observed and this may be due to 
ethnic differences.
 The number of DC-SIGN exon 4 repeat was 
highly conserved, with 7.5/7.5 genotype being the 
most common repeat genotype in all study groups. 
No association with susceptibility or resistance to 
HIV and TB was observed. Studies from north India, 
South Africa and Thailand also revealed no association 
between DC SIGN exon 4 repeat polymorphism and 
TB or HIV10,14,28,. Further studies on the other single 
nucleotide polymorphisms in the promoter region 
of DC-SIGN gene that influence its expression may 
identify the variants that are associated with HIV/TB 
in south Indian population.
 In the present study, it is also possible that certain 
proportion of the HIV patients might have progressed 
to full blown AIDS cases and tuberculosis among 
HIV patients might also be due to the result of disease 
progression. However, the influence of chemokine and 
chemokine receptor gene variants on HIV-1 disease 
progression could not be assessed due to the non 
availability of data on CD4+ T cell count and viral load. 
Since HIV+TB+ patients were older than HIV+TB- 
patients, it is also conceivable that HIV+TB- patients 
would become HIV+TB+ gradually. Moreover, the 
period of HIV exposure is also not known among the 
patients, a lead-time bias in our sample recruitment 
cannot be excluded. To the best of our knowledge, this 
is the first study to explore the role of chemokine and 
chemokine receptor gene variants in susceptibility to 
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tuberculosis in the context of HIV infection. Genetic 
factors might play a role in determining the progression 
from latent to active disease in TB endemic countries. A 
better understanding of these factors could help target 
preventive strategies to those HIV infected individuals 
most likely to develop tuberculosis.  
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